Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.
Swiss researchers analyzed shifts in kidney function among those switching from the old form of the HIV medication to the new one.
A late-stage trial randomized people taking a stable HIV regimen to switch to Dovato or stay on their current antiretrovirals.
However, Tivicay plus Descovy was associated with greater weight gain, especially among women.
Researchers compared data on more than 9,000 people with HIV who took either version of tenofovir.
Tenofovir disoproxil fumarate is found in Truvada, Viread, Atripla, Complera and Stribild.
The insert contained the antiretrovirals tenofovir alafenamide, known as TAF, and Vitekta (elvitegravir).
The antiretroviral GS-6207 is injected under the skin and would need to be combined with other meds to fully suppress HIV.
Gilead has based its entire HIV drug portfolio on updating tenofovir, ostensibly to make it safer for bones and kidneys.
Researchers call for closer cardiovascular monitoring for those switching from the TDF form of the drug to the TAF version.
Gilead Sciences has released multiple combo tablets that contain the updated tenofovir, which is linked to improved bone and kidney makers.
Researchers compared switching to Symtuza with staying on an effective regimen of a boosted protease inhibitor plus Truvada.
The single-tablet antiretroviral regimen includes Janssen’s darunavir plus Gilead’s cobicistat, emtricitabine and tenofovir alafenamide.
That’s compared with HIV-negative men.
A new analysis finds that Gilead Sciences’ updated version of its key antiretroviral tenofovir may not actually offer any safety benefits.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.